Inotiv (NOTV) Stock Price, News & Analysis

Company Overview

Inotiv, Inc., formerly known as Bioanalytical Systems, Inc. (NASDAQ: NOTV), is a global contract research organization (CRO) specializing in preclinical drug discovery, development and testing services. The company partners with pharmaceutical, biotech and medical device companies to advance candidate molecules through early‐stage research and safety assessment. Inotiv’s integrated platform spans in vivo and in vitro pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, pathology and bioanalysis.

The company’s core service offerings include discovery pharmacology, safety assessment toxicology, pathology, bioanalysis and regulatory support. Inotiv’s facilities are designed to meet stringent regulatory standards and accommodate a wide range of study types, from small molecule and biologic evaluation to specialty services addressing ophthalmology, neuroscience and cardiovascular indications. With laboratory locations in the United States, Europe and Asia Pacific, Inotiv serves a diverse client base seeking scalable, GLP‐compliant research solutions.

Inotiv traces its roots to the founding of Bioanalytical Systems, Inc. in the early 1980s and formally adopted the Inotiv name in 2020 to reflect its broadening suite of scientific services. Headquartered in West Lafayette, Indiana, the company has grown through strategic investments in technology platforms and site expansions. Inotiv is led by a management team with deep expertise in biopharmaceutical research and CRO operations, positioning the company to support clients from target identification through IND filing and beyond.

Key Stats

• Today's Range: $0.30 to $0.32
• 50-Day Range: $0.23 to $0.45
• 52-Week Range: $0.22 to $3.32
• Volume: 82,361 shs
• Average Volume: 590,241 shs
• Market Capitalization: $10.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Hold

Inotiv Stock Analysis - MarketRank™

Inotiv scored higher than 45% of companies evaluated by MarketBeat, and ranked 698th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Inotiv has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Inotiv has a consensus price target of $1.50, representing about 398.3% upside from its current price of $0.30.

Amount of Analyst Coverage

Inotiv has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Inotiv is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inotiv is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inotiv has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.58% of the float of Inotiv has been sold short.

Short Interest Ratio / Days to Cover

Inotiv has a short interest ratio ("days to cover") of 2.16, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inotiv has recently increased by 0.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inotiv does not currently pay a dividend.

Dividend Growth

Inotiv does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.81

News Sentiment

Inotiv has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Inotiv this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Inotiv insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,495.00 in company stock.

Percentage Held by Insiders

7.80% of the stock of Inotiv is held by insiders.

Percentage Held by Institutions

18.17% of the stock of Inotiv is held by institutions.

NOTV Stock Analysis - Frequently Asked Questions

How have NOTV shares performed this year?

Inotiv's stock was trading at $0.5621 at the beginning of the year. Since then, NOTV stock has decreased by 46.5% and is now trading at $0.3010.

How were Inotiv's earnings last quarter?

Inotiv, Inc. (NASDAQ:NOTV) issued its quarterly earnings results on Wednesday, December, 3rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.17. The business earned $138.14 million during the quarter, compared to the consensus estimate of $133.36 million. Inotiv had a negative trailing twelve-month return on equity of 28.95% and a negative net margin of 13.50%.
Read the conference call transcript.

Who are Inotiv's major shareholders?

Top institutional investors of Inotiv include Fifth Third Bancorp (0.41%). Insiders that own company stock include Robert Jr Leasure, John E Sagartz, David Landman, John Gregory Beattie, R Matthew Neff, Beth A Taylor, Nigel Brown, Jeffrey Brennan Freeman and Michael Garrett.
View institutional ownership trends.

How do I buy shares of Inotiv?

Shares of NOTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inotiv own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inotiv investors own include NVIDIA (NVDA), Arista Networks (ANET), Alibaba Group (BABA), Meta Platforms (META), Super Micro Computer (SMCI), Weatherford International (WFRD) and Axcelis Technologies (ACLS).

Company Calendar

• Last Earnings: 12/03/2025
• Today: 5/06/2026
• Next Earnings (Estimated): 5/06/2026
• Status update: 6/10/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:NOTV
• CIK: 720154
• Web: www.inotivco.com
• Phone: (765) 463-4527
• Fax: 765-497-1102
• Employees: 2,046
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Inotiv: $1.50
• High Price Target: $1.50
• Low Price Target: $1.50
• Potential Upside/Downside: +398.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.62 million
• Net Margins: -13.50%
• Pretax Margin: -17.11%
• Return on Equity: -28.95%
• Return on Assets: -5.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.30
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: $513.02 million
• Price / Sales: 0.02
• Cash Flow: $0.10 per share
• Price / Cash Flow: 3.12
• Book Value: $3.96 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 34,400,000
• Free Float: 31,712,000
• Market Cap: $10.35 million
• Optionable: Optionable
• Beta: 3.82